Suchergebnisse - "Cook, Gordon"

PubPharm (15)

1

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

2

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

3

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]) : a randomised, open-label, phase 3 trial

enthalten in: British journal of haematology | 2019

von Cook, G. | Royle, K. | O'Connor, S. | +20

4

Mutational Spectrum, Copy Number Changes, and Outcome : Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2015

von Walker, B. | Boyle, E. | Wardell, C. | +24

5

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2014

von Cook, G. | Williams, C. | Brown, J. | +15

ErratumIn: Lancet Oncol. 2014 Aug;15(9):e365 Dosage error in article text

6

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma : Medical Research Council Myeloma IX Study results

enthalten in: British journal of haematology | 2014

von Jackson, G. | Morgan, G. | Davies, F. | +17

7

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden

enthalten in: Bone marrow transplantation | 2013

von Blijlevens, N. | de Château, M. | Krivan, G. | +60

8

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma : impact on outcome in the Medical Research Council Myeloma IX Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2013

von Rawstron, A. | Child, J. | de Tute, R. | +12

ErratumIn: J Clin Oncol. 2013 Dec 1;31(34):4383

9

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX) : secondary outcomes from a randomised controlled trial

enthalten in: The Lancet. Oncology | 2011

von Morgan, G. | Child, J. | Gregory, W. | +17

CommentIn: Lancet Oncol. 2011 Aug;12(8):711-2. - PMID 21771569

10

Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years

enthalten in: British journal of haematology | 2011

von Parrish, C. | Cromack, J. | Feyler, S. | +3